menu

MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

News & Library

HomeNews & Library
HomeNews & Library

Press release

December 10, 2020: GILEAD  SCIENCES  TO  ACQUIRE  MYR  GMBH 

link: http://www.prnewswire.com/news-releases/gilead-sciences-to-acquire-myr-gmbh-301190500.html?tc=eml_cleartime

 

 

Biotechnologie 2020: „Bench to bedside“

MYR Pharmaceuticals GmbH: Kampf gegen Hepatitis

Eine case study in Plattform Life Sciences, Ausgabe September 2020 (in German). More...

 

Press releases

September 17, 2020 - MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria. More...

 

Scientific Publications

MYR Pharma's scientific founders and collaborators have published numerous papers in top peer reviewed journals describing Myrcludex B mechanism of action and the results of preclinical and clinical development. Myrcludex B has been highlighted in many recent review articles as one of the leading drugs for the treatment of HBV and HDV. More...